Cipla to set up Rs.1.3-bn biotech plant in SA
The Dollar Business Bureau Cipla BioTec, the research and development subsidiary of Cipla, will invest around Rs.1.3 billion to set up state-of-the-art manufacturing plant for the production of biosimilars in South Africa. The global pharmaceutical firm owns the third largest pharma company in South Africa - Cipla Medpro. Subhanu Saxena, MD and Global CEO of Cipla Ltd said that the investment will facilitate to create the first bio-cluster in Africa. A state-of-the-art manufacturing base in South Africa will provide new opportunities for the partners in supply chain. This will further allow high level research efforts to sustain in South Africa. The biotech manufacturing unit will attract research from global institutions. This facility will have all the required design capabilities. It will seek regulatory approvals ...
Indian pharma major to acquire two US firms, deal worth $550 mn
The Dollar Business Bureau Cipla EU, the UK arm of the Mumba-based Cipla Ltd., has entered into definitive agreements to acquire two US-based firms— InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc. The deal which is subject to certain closing conditions is valued at $550 million. This acquisition, which is being seen as the second landmark acquisition in Cipla’s history, will give the company scale in the US generics market through a wide range of product portfolio in CNS, CVS, anti-infectives, diabetes as well as other value added generic drugs, , the company said in a statement on Friday. While acquisition of InvaGen, a skilled R&D organization, offers a large capacity manufacturing base in Hauppauge, New York, Exelan provides Cipla with an access ...
